NM LEEP Cohort 5 pictured at the NM LEEP Finals Event in September 2025 are, from left, Holly Eagleston, Stephen Buchanan, ...
- Treatment with infigratinib at the Cohort 5 dose level resulted in a significant and robust increase in annual height velocity (AHV), with a mean change of +3.38 cm/year from baseline - 83% of ...
- 83% of children in Cohort 5 responded to infigratinib, as defined by an increase from baseline AHV of at least 25%. The mean change from baseline in AHV of responders was +4.08 cm/year - Early but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results